source
- Ultragenyx's Angelman gene therapy fails Phase 3, company to cut expensesUltragenyx reported that its late‑stage Aspire trial of apazunersen in Angelman syndrome did not meet its primary or secondary endpoints. The primary goal of improving the Bayley‑4 cognitive raw sc…
- FDA requests public input to accelerate botanical drug product developmentThe U.S. Food and Drug Administration issued a request for information (RFI) to collect public comments on ways to move botanical drug products forward. Botanical drug products are derived from pl…